Novo Nordisk's Two-Speed Story: Analysts Split as Oral Ambitions Meet Injectable Momentum

Novo Nordisk shares stabilize near €41 as JPMorgan raises target on strong Wegovy uptake, while oral pipeline and Awiqli launch shape future growth.

The Danish drugmaker's share price has settled into a narrow trading band around 41 euros, but beneath that calm surface lies a strategic narrative pulling in two directions at once. One camp of analysts sees a company whose international injectable franchise is outstripping expectations; the other watches the oral pipeline with growing caution.

That tension came into sharp relief on August 24, when JPMorgan's Richard Vosser lifted his price target on Novo Nordisk from 250 to 275 Danish kroner while holding the rating at Neutral. The move was driven by two factors: reduced generic erosion risk for Ozempic and stronger-than-anticipated international uptake of Wegovy outside the United States. Vosser also raised the bank's 2026 revenue forecast by 5 percent and bumped earnings-per-share estimates for 2026 through 2030 by 4 to 8 percent.

The market responded favorably, with the stock climbing 3.5 percent on Tuesday to 41.60 euros. That puts the shares just shy of their 50-day moving average of 41.71 euros and roughly 3.4 percent above the 200-day line — a technical picture suggesting the stock has stabilized after shedding 12 percent over the preceding twelve months.

A Pipeline Betting on the Pill

The analyst attention comes as Novo Nordisk pushes forward on multiple fronts. The company announced in August that its oral version of Wegovy would soon launch in Germany, a move announced alongside its half-year results. The significance extends beyond a single market: the obesity treatment landscape has been dominated by injections, creating barriers for needle-averse patients and logistical complications around cold-chain storage. An oral formulation lowers that threshold considerably.

CEO Mike Doustdar framed the strategy in a recent Reuters interview, arguing that the obesity market is not heading toward a winner-take-all showdown with Eli Lilly. Oral options, he contends, will expand overall demand rather than merely redistribute market share between the two rivals.

The clinical evidence for that thesis is still being assembled. Since mid-August, the company has been running the OASIS-5 late-stage trial across 62 sites in the US and Europe, designed to identify the lowest effective maintenance dose of the Wegovy pill. Results are not expected until 2028 — a timeline that underscores how deliberately Novo Nordisk is playing this hand.

Diversification Beyond GLP-1

Semaglutide may dominate the headlines, but the company is quietly building a second pillar. August brought the US launch of Awiqli, a basal insulin that represents an attempt to establish a foothold outside the GLP-1 class entirely.

Research operations are also being reshaped. A strategic partnership with AWS, announced in August, aims to accelerate drug development and will establish an AI hub in London. The logic is straightforward: whoever wants to build tomorrow's pipeline needs today's computing power.

Legal Defense and Capital Returns

On the legal front, a Dutch court granted Novo Nordisk a preliminary injunction against Ceban in a patent dispute involving semaglutide nasal sprays. The case may read as technical, but it reflects a broader reality: the more successful a molecule becomes, the more challengers probe the edges of its patent protection.

The company is also keeping its options open on the M&A front, with the board confirming it is evaluating several acquisition candidates to accelerate research. Meanwhile, the share buyback program launched in May continues, with an update at the end of August — a signal that capital returns to shareholders remain a priority even amid heavy growth investment.

The Bear Case Still Lingers

Not everyone is convinced. Berenberg downgraded the stock from Buy to Hold on August 12, cutting its price target from 50 to 47 US dollars on expectations that competition in the oral obesity market will intensify in the second half of the year.

JPMorgan's own analysis contains a similar caveat. While the injectable Wegovy is gaining ground internationally, the bank sees US launch momentum for the oral version fading and has trimmed its 2026 forecasts for that product accordingly. The overall picture, on constant-currency terms, is for flat revenue in 2026, followed by roughly 1 percent growth in 2027 and about 2 percent in 2028. Meaningful acceleration, the analysts suggest, hinges on the progress of the experimental candidate Zenagamtide.

The stock's 40 percent volatility on a 30-day basis suggests the market continues to price in that uncertainty. The shares currently trade at 41.30 euros against a 52-week high of 54.86 euros — a gap of roughly a quarter that reflects how far expectations have been trimmed over the past year.

The central question for investors is no longer whether Novo Nordisk retains growth potential, but whether the pill can genuinely challenge the injection before competitors close the gap. With OASIS-5 running until 2028, that answer will take years to emerge. The company has committed to a long-distance race with an open outcome — and the analyst community remains divided on who crosses the finish line first.